Bret Jensen

|RSS

Currently the editor of "The Biotech Forum," Bret Jensen was chief investment strategist for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami, from 2008-2011. The fund was in the top 5% of long/short hedge funds for total return in its first full year (2009), as ranked by Hedgeco fund database (more than 450 funds in category). Prior to this, he spent a decade as technology director of a Fortune 100 firm.Expand

Jensen has been a top-5%-ranked financial analyst and blogger since 2013, according to TipRanks. He holds a Bachelor of Science degree in finance from Arizona State University.

Follow Bret on Twitter: @Bret_Jensen.Collapse

By

Bret Jensen

 | May 26, 2016 | 1:10 PM EDT
Market slightly down as it digests two days of gains with less than three hours to go in trading. Oil also slightly down after moving above $50 a...
By

Bret Jensen

 | May 26, 2016 | 11:30 AM EDT

There should be lots of pent-up demand, provided there's no recession and job growth stays steady.

By

Bret Jensen

 | May 26, 2016 | 9:46 AM EDT
Market flat after two nice day of gains. Oil up above $50 a barrel, will be interesting to see if this restarts drilling if crude stays above these...
By

Bret Jensen

 | May 25, 2016 | 12:35 PM EDT
Market having another strong day. Energy shares strong as oil tries to broach $50 a barrel. Seeing some continuing strength in some of my beaten...
By

Bret Jensen

 | May 25, 2016 | 10:24 AM EDT
Market is building nicely on yesterday's gains. Biotech continues to gain as Bloomberg report states biotech juggernauts Gilead Sciences (GILD) and...
By

Bret Jensen

 | May 24, 2016 | 1:11 PM EDT
Very broad rally this Tuesday as all the major indices are up over one percent and 29 of the 30 Dow components are up on the day as well. Biotech...
By

Bret Jensen

 | May 24, 2016 | 11:00 AM EDT

Keep cash on hand and be ready for oportunities as they arise.

By

Bret Jensen

 | May 24, 2016 | 8:00 AM EDT
Market looks like it will open slightly higher based on futures. Just glancing through the headlines from the other side of the pond and the...
By

Bret Jensen

 | May 23, 2016 | 11:00 AM EDT

FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.

By

Bret Jensen

 | May 23, 2016 | 10:42 AM EDT
Biotech trying to make it two weeks in a row for solid gains. Small cap XenoPort (XNPT) gets acquired by privately held Arbor Pharma for almost $500...

BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.